Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASR | P41180 | 1/20 | 0.33 |
| ▸ | FFAR1 | O14842 | 6/20 | 0.32 |
| ▸ | LTB4R | Q15722 | 1/20 | 0.31 |
| ▸ | RORC | P51449 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26565122 | 0.92 | CASR (0.32) | CASRLTB4R | |
| SCHEMBL26564931 | 0.90 | FFAR1 (0.34) | CASRFFAR1LTB4RRORC | |
| SCHEMBL26564919 | 0.89 | SOS1 (0.33) | CASRFFAR1LTB4RRORC | |
| SCHEMBL26564956 | 0.86 | FFAR1 (0.34) | FFAR1LTB4R | |
| SCHEMBL25259300 | 0.83 | L3MBTL1 (0.41) | LTB4R | |
| SCHEMBL31059229 | 0.83 | L3MBTL1 (0.41) | LTB4R | |
| SCHEMBL26565050 | 0.82 | RORC (0.33) | CASRFFAR1LTB4RRORC | |
| SCHEMBL26565119 | 0.78 | LTB4R (0.33) | FFAR1LTB4R | |
| SCHEMBL26565169 | 0.77 | LTB4R (0.35) | CASRLTB4RRORC | |
| SCHEMBL26564916 | 0.76 | CNR2 (0.39) | FFAR1LTB4R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12018011-B2 | Macrocyclic compounds and compositions, and methods of preparing and using the same | KURA ONCOLOGY, INC. (US) | 2024-06-25 | — | — | US | disclosed |
| US-20230322711-A1 | MACROCYCLIC COMPOUNDS AND COMPOSITIONS, AND METHODS OF PREPARING AND USING THE SAME | WUXI APPTEC (HONG KONG) LIMITED (CN) | 2023-10-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12018011-B2 | Macrocyclic compounds and compositions, and methods of preparing and using the same | FNTA, FDPS, GGPS1 | CASR 4852/4885FFAR1 2973/4885LTB4R 2287/4885 |
| US-20230322711-A1 | MACROCYCLIC COMPOUNDS AND COMPOSITIONS, AND METHODS OF PREPARING AND USING THE SAME | FNTA, FDPS, GGPS1 | CASR 4852/4885FFAR1 2973/4885LTB4R 2287/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.